Literature DB >> 10983733

Potential novel uses of thalidomide: focus on palliative care.

V Peuckmann1, M Fisch, E Bruera.   

Abstract

Thalidomide, after being banned from the market in the early 1960s because of the worldwide teratogenesis disaster, is currently being rediscovered because of its multiple therapeutic effects in various serious diseases and symptoms. Original studies examined the anxiolytic, mild hypnotic, anti-emetic and adjuvant analgesic properties of this drug. Subsequently, thalidomide was found to be highly effective in managing the cutaneous manifestations of leprosy (erythema nodosum leprosum) and even to be superior to aspirin (acetylsalicylic acid) in controlling leprosy-associated fever. Recent research shows promising results with thalidomide in patients with progressive bodyweight loss related to advanced cancer and HIV infection. Thalidomide therapy of diseases such as tuberculosis, sarcoidosis, aphthous ulcers in HIV syndrome and Behcet's disease, rheumatoid arthritis, multiple myeloma, graft-versus-host disease, pyoderma gangrenosum, inflammatory bowel disease, Sjögren's syndrome, lupus erythematosus and a variety of solid tumours is currently being explored. Furthermore, in preliminary studies, thalidomide has been found to be effective in several syndromes related to advanced cancer, such as the cancer cachexia syndrome, chronic nausea, insomnia, profuse sweating and pain. Whether thalidomide has a therapeutic effect on neoplastic fever has yet to be elucidated. These intriguing features make the use of the drug potentially attractive for palliative care. In addition, by a distinct mechanism of action compared with most other drugs, thalidomide offers the possibility of combined treatment with other agents with non-overlapping toxicities. The mechanism of action of thalidomide is probably based on the suppression of tumour necrosis factor-alpha and the modulation of interleukins. However, it is not possible to identify a single dominant mechanism, since the action of cytokines and the effect of thalidomide appear to be complex. This review article discusses the original uses and teratogenic effects of thalidomide within its historical context and, linking recent research at the molecular level with clinical findings, aims to provide the reader with insight into the current understanding of its biological actions, toxicities and potential benefits.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10983733     DOI: 10.2165/00003495-200060020-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  98 in total

1.  Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL).

Authors:  E P Sampaio; M O Moraes; J A Nery; A R Santos; H C Matos; E N Sarno
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

2.  Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

Authors:  J M Jacobson; J S Greenspan; J Spritzler; N Ketter; J L Fahey; J B Jackson; L Fox; M Chernoff; A W Wu; L A MacPhail; G J Vasquez; D A Wohl
Journal:  N Engl J Med       Date:  1997-05-22       Impact factor: 91.245

3.  Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine- and endotoxin-activated endothelium.

Authors:  S Dunzendorfer; P Schratzberger; N Reinisch; C M Kähler; C J Wiedermann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1997-11       Impact factor: 3.000

4.  The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus.

Authors:  P Haslett; M Hempstead; C Seidman; J Diakun; D Vasquez; V H Freedman; G Kaplan
Journal:  AIDS Res Hum Retroviruses       Date:  1997-08-10       Impact factor: 2.205

5.  Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent.

Authors:  K S Bauer; S C Dixon; W D Figg
Journal:  Biochem Pharmacol       Date:  1998-06-01       Impact factor: 5.858

6.  WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients.

Authors:  C G Iyer; J Languillon; K Ramanujam; G Tarabini-Castellani; J T De las Aguas; L M Bechelli; K Uemura; V Martinez Dominguez; T Sundaresan
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

7.  Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis.

Authors:  P Wolkenstein; J Latarjet; J C Roujeau; C Duguet; S Boudeau; L Vaillant; M Maignan; M H Schuhmacher; B Milpied; A Pilorget; H Bocquet; C Brun-Buisson; J Revuz
Journal:  Lancet       Date:  1998-11-14       Impact factor: 79.321

8.  Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice.

Authors:  L R Leon; A A White; M J Kluger
Journal:  Am J Physiol       Date:  1998-07

9.  Thalidomide. A promising new treatment for rheumatoid arthritis.

Authors:  O Gutiérrez-Rodríguez
Journal:  Arthritis Rheum       Date:  1984-10

10.  Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin.

Authors:  J R Gordon; S J Galli
Journal:  Nature       Date:  1990-07-19       Impact factor: 49.962

View more
  14 in total

Review 1.  Drug-induced congenital defects: strategies to reduce the incidence.

Authors:  M De Santis; B Carducci; A F Cavaliere; L De Santis; G Straface; A Caruso
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Extraintestinal Complications of Inflammatory Bowel Disease.

Authors:  Ad A. van Bodegraven; Ben A. C. Dijkmans; Paul Lips; Tom J. Stoof; A. Salvador Peña; Stephan G. M. Meuwissen
Journal:  Curr Treat Options Gastroenterol       Date:  2001-06

Review 3.  Thalidomide in cancer treatment: a potential role in the elderly?

Authors:  Shufeng Zhou; Philip Kestell; Malcolm D Tingle; James W Paxton
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

4.  Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.

Authors:  Hsueh-Erh Chiou; Tsang-En Wang; Ying-Yue Wang; Hui-Wen Liu
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

Review 5.  New drugs for the anorexia-cachexia syndrome.

Authors:  Mellar P Davis
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

Review 6.  Thalidomide and its derivatives: emerging from the wilderness.

Authors:  J N Gordon; P M Goggin
Journal:  Postgrad Med J       Date:  2003-03       Impact factor: 2.401

7.  Stabilization of a progressive hemangioblastoma under treatment with thalidomide.

Authors:  Maria Piribauer; Thomas Czech; Karin Dieckmann; Peter Birner; Johannes A Hainfellner; Daniela Prayer; Barbara Fazeny-Dörner; Georg Weinländer; Christine Marosi
Journal:  J Neurooncol       Date:  2004-02       Impact factor: 4.130

8.  The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development.

Authors:  Waqas Rehman; Lisa M Arfons; Hillard M Lazarus
Journal:  Ther Adv Hematol       Date:  2011-10

Review 9.  Pyoderma gangrenosum: pathogenetic oriented treatment approaches.

Authors:  Uwe Wollina; Georgi Tchernev
Journal:  Wien Med Wochenschr       Date:  2014-06-05

10.  Thalidomide treatment prevents chronic graft rejection after aortic transplantation in rats - an experimental study.

Authors:  Katharine K Miller; Dong Wang; Xiaomeng Hu; Xiaoqin Hua; Tobias Deuse; Evgenios Neofytou; Thomas Renne; Joachim Velden; Hermann Reichenspurner; Sonja Schrepfer; Daniel Bernstein
Journal:  Transpl Int       Date:  2017-08-14       Impact factor: 3.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.